Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation

European Neuropsychopharmacology

Volumn 25, Issue 10, 2015, Pages 1631-1636

  Rolland, Benjamin ^a,b   Labreuche, Julien ^a   Duhamel, Alain ^a,c   Deheul, Sylvie ^a   Gautier, Sophie ^b,d   Auffret, Marine ^d   Pignon, Baptiste ^a   Valin, Thomas ^d   Bordet, Régis ^a,b,d   Cottencin, Olivier ^a,e  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c Faculté de Médecine Pôle Recherché   (France)

^d CH Douai ^*  (France)

^e Univ Lille   (France)

Author keywords

Alcohol related disorders; Alcoholism; Baclofen; Drug related side effects and adverse reactions; Ethanol; GABA agonists

Indexed keywords

ALCOHOL; BACLOFEN; CENTRAL DEPRESSANT AGENT; DRUGS USED IN THE TREATMENT OF ADDICTION; HYPNOTIC SEDATIVE AGENT;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG MEGADOSE; DSM-IV-TR; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEDATION; TREATMENT DURATION; VISUAL ANALOG SCALE; ADVERSE EFFECTS; DOSE RESPONSE; FEMALE; MULTIVARIATE ANALYSIS; RISK;

ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOLISM; BACLOFEN; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK;

EID: 84943357416     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.05.008     Document Type: Article

References (23)

1. Agence Française du Médicament et des produits de santé, 2014. Recommandation temporaire d'utilisation (RTU) pour le baclofène - Point d'information Temporary recommendation for use (TRU) for baclofen. Available online at: (accessed 10.03.15). http://ansm.sante.fr/S-informer/Actualite/Une-recommandation-temporaire-d-utilisation-RTU-est-accordee-pour-le-baclofene-Point-d-information.
2. Bertholet N., Winter M.R., Cheng D.M., Samet J.H., Saitz R. How accurate are blood (or breath) tests for identifying self-reported heavy drinking among people with alcohol dependence?. Alcohol Alcohol. 2014, 49(4):423-429.
3. Case M.A., Burwick H.A., Volpp K.G., Patel M.S. Accuracy of smartphone applications and wearable devices for tracking physical activity data. JAMA 2015, 313(6):625-626.
4. ClinicalTrials.gov-a. Baclofen for the Treatment of Alcohol Drinkers. (accessed 10.03.2015. http://www.clinicaltrials.gov/ct2/show/NCT01604330?term=bacloville&rank=1.
5. ClinicalTrials.gov-b. Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients. (accessed 10.03.2015. http://www.clinicaltrials.gov/ct2/show/NCT01738282?term=alpadir&rank=1.
6. Deshpande P.R., Rajan S., Sudeepthi B.L., Abdul Nazir C.P. Patient-reported outcomes: a new era in clinical research. Perspect. Clin. Res. 2011, 2(4):137-144.
7. Dupouy J., Fournier J-.P., Jouanjus E., Palmaro A., Poutrain J-C., Oustric S., Lapeyre-Mestre M. Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns-a cohort study. Eur. Neuropsychopharmacol. 2014, 24(2):192-199.
8. Evans S.M., Bisaga A. Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol. Clin. Exp. Res. 2009, 33(1):19-30.
9. Food and Drug Administration, 2015. What is a serious adverse event?. Available at: (accessed 10.03.2015). http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm.
10. Hedden S.L., Woolson R.F., Carter R.E., Palesch Y., Upadhyaya H.P., Malcolm R.J. The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse clinical trials. J. Subst. Abuse Treat. 2009, 37(1):54-63.
11. Kiel L.B., Hoegberg L.C.G., Jansen T., Petersen JA., Dalhoff K.P. A nationwide register-based survey of baclofen toxicity. Basic Clin. Pharmacol. Toxicol. 2015, 116(5):452-456.
12. Lafleur K.J. Will adequate sedation assessment include the use of actigraphy in the future?. Am. J. Crit. Care 2005, 14(1):61-63.
13. Müller C.A., Geisel O., Pelz P., Higl V., Krüger J., Stickel A., Beck A., Wernecke K.D., Hellweg R., Heinz A. Eur. Neuropsychopharmacol. 2015, 10.1016/j.euroneuro.2015.04.002.
14. Mackenzie A., Funderburk F.R., Allen R.P., Stefan R.L. The characteristics of alcoholics frequently lost to follow-up. J. Stud. Alcohol 1987, 48(2):119-123.
15. National Institute on Alcohol Abuse and Alcoholism. What is « at-risk » or « heavy » drinking? Available at: (accessed 10.03.2015). http://rethinkingdrinking.niaaa.nih.gov/IsYourDrinkingPatternRisky/WhatsAtRiskOrHeavyDrinking.asp.
16. Rolland B., Deheul S., Danel T., Bordet R., Cottencin O. A system of prescriptions without drug approval: example of baclofen. Therapie 2010, 65(6):511-518.
17. Rolland B., Bordet R., Cottencin O. Alcohol-dependence: the current French craze for baclofen. Addiction 2012, 107(4):848-849.
18. Rolland B., Paille F., Fleury B., Cottencin O., Benyamina A., Aubin H.J. Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey. PLoS One 2014, 9(6):e98062.
19. Rolland B., Valin T., Langlois C., Auffret M., Gautier S., Deheul S., Danel T., Bordet R., Cottencin O. Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. Int. Clin. Psychopharmacol. 2015, 30(1):49-53.
20. Sachais B.A., Logue J.N., Carey M.S. Baclofen, a new antispastic drug. a controlled, multicenter trial in patients with multiple sclerosis. Arch. Neurol. 1977, 34(7):422-428.
21. Sobell L.C., Sobell M.B., Leo G.I., Cancilla A. Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br. J. Addict. 1988, 83(4):393-402.
22. Société Française d'Alcoologie, 2015. Good Practice Recommendation. Alcohol misuse: screening, diagnosis, and treatment. Available at: (accessed 10.03.2015). http://www.sfalcoologie.asso.fr/download/SFA-GPR-AlcoholMisuse.pdf?PHPSESSID=5b26fb3d20947af67a5f63e5f6689df8.
23. Zeger S.L., Liang K.Y., Albert P.S. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988, 44(4):1049-1060.